GMAB Research and Charts

GMAB - Genmab A/S ADR (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-10-29)

Last 28.95	Change ⇓ -0.18 (-0.62%)	Volume 1,071,350
	Open 29.28	High 29.30	Low 28.65

8EMA (Daily) 30.28	40EMA (Daily) 29.46	50EMA (Daily) 28.81	STO (Daily) 6.781	MACD Hist (Daily) -0.701
8EMA (Weekly) 29.676	40EMA (Weekly) 25.16	50EMA (Weekly) 24.98	STO (Weekly) 83.433	MACD Hist (Weekly) 0.110


Company Profile
Genmab is a Copenhagen-based cancer drug developer best known for its antibody technology platforms, DuoBody and HexaBody, and multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company is the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis) and has several pipeline candidates targeting other oncologic indications and autoimmune diseases.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.